Kura Oncology Total Assets Growth & History (KURA)
Kura Oncology's total assets was $738.4M for fiscal 2025.
View full Kura Oncology company overviewKura Oncology annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $738.4M | −$21.8M | −2.87% |
| 2024 | 2024-12-31 | $760.2M | $311.2M | +69.32% |
| 2023 | 2023-12-31 | $448.9M | −$7.4M | −1.62% |
| 2022 | 2022-12-31 | $456.3M | −$77.7M | −14.56% |
| 2021 | 2021-12-31 | $534.1M | −$113.2M | −17.48% |
| 2020 | 2020-12-31 | $647.2M | $405.2M | +167.47% |
| 2019 | 2019-12-31 | $242.0M | $59.6M | +32.68% |
| 2018 | 2018-12-31 | $182.4M | $86.5M | +90.27% |
| 2017 | 2017-12-31 | $95.9M | $26.0M | +37.28% |
| 2016 | 2016-12-31 | $69.8M | −$17.4M | −19.98% |
| 2015 | 2015-12-31 | $87.3M | $85.9M | +6232.29% |
| 2014 | 2014-12-31 | $1.4M | $1.4M | +15096.29% |
| 2013 | 2013-12-31 | $9,068 | $766 | +9.23% |
| 2012 | 2012-12-31 | $8,302 | $1,582 | +23.54% |
| 2011 | 2011-12-31 | $6,720 | −$22,678 | −77.14% |
| 2010 | 2010-12-31 | $29,398 | — | — |
Kura Oncology quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $587.8M | −$94.6M | −13.87% |
| Q1 2026 | 2026-03-31 | $652.6M | −$91.2M | −12.26% |
| Q4 2025 | 2025-12-31 | $738.4M | −$21.8M | −2.87% |
| Q3 2025 | 2025-09-30 | $649.4M | $170.5M | +35.62% |
| Q2 2025 | 2025-06-30 | $682.4M | $167.3M | +32.48% |
| Q1 2025 | 2025-03-31 | $743.8M | $189.9M | +34.28% |
| Q4 2024 | 2024-12-31 | $760.2M | $311.2M | +69.32% |
| Q3 2024 | 2024-09-30 | $478.8M | $5.1M | +1.07% |
| Q2 2024 | 2024-06-30 | $515.1M | $20.4M | +4.12% |
| Q1 2024 | 2024-03-31 | $553.9M | $127.9M | +30.03% |
| Q4 2023 | 2023-12-31 | $448.9M | −$7.4M | −1.62% |
| Q3 2023 | 2023-09-30 | $473.8M | $25.8M | +5.76% |
| Q2 2023 | 2023-06-30 | $494.7M | $23.3M | +4.95% |
| Q1 2023 | 2023-03-31 | $426.0M | −$72.6M | −14.56% |
| Q4 2022 | 2022-12-31 | $456.3M | −$77.7M | −14.56% |
| Q3 2022 | 2022-09-30 | $448.0M | −$113.2M | −20.16% |
| Q2 2022 | 2022-06-30 | $471.4M | −$113.5M | −19.40% |
| Q1 2022 | 2022-03-31 | $498.6M | −$121.7M | −19.62% |
| Q4 2021 | 2021-12-31 | $534.1M | −$113.2M | −17.48% |
| Q3 2021 | 2021-09-30 | $561.1M | $221.6M | +65.25% |
| Q2 2021 | 2021-06-30 | $584.9M | $231.9M | +65.69% |
| Q1 2021 | 2021-03-31 | $620.3M | $393.8M | +173.89% |
| Q4 2020 | 2020-12-31 | $647.2M | $405.2M | +167.47% |
| Q3 2020 | 2020-09-30 | $339.6M | $85.0M | +33.37% |
| Q2 2020 | 2020-06-30 | $353.0M | $87.3M | +32.86% |
| Q1 2020 | 2020-03-31 | $226.5M | $56.8M | +33.51% |
| Q4 2019 | 2019-12-31 | $242.0M | $59.6M | +32.68% |
| Q3 2019 | 2019-09-30 | $254.6M | $63.1M | +32.95% |
| Q2 2019 | 2019-06-30 | $265.7M | $136.1M | +104.96% |
| Q1 2019 | 2019-03-31 | $169.6M | $28.2M | +19.91% |
| Q4 2018 | 2018-12-31 | $182.4M | $86.5M | +90.27% |
| Q3 2018 | 2018-09-30 | $191.5M | $88.4M | +85.71% |
| Q2 2018 | 2018-06-30 | $129.6M | $73.8M | +132.11% |
| Q1 2018 | 2018-03-31 | $141.5M | $79.5M | +128.46% |
| Q4 2017 | 2017-12-31 | $95.9M | $26.0M | +37.28% |
| Q3 2017 | 2017-09-30 | $103.1M | $26.8M | +35.14% |
| Q2 2017 | 2017-06-30 | $55.8M | −$25.9M | −31.68% |
| Q1 2017 | 2017-03-31 | $61.9M | −$18.5M | −22.97% |
| Q4 2016 | 2016-12-31 | $69.8M | −$17.4M | −19.98% |
| Q3 2016 | 2016-09-30 | $76.3M | $33.5M | +78.17% |
| Q2 2016 | 2016-06-30 | $81.7M | $34.2M | +71.98% |
| Q1 2016 | 2016-03-31 | $80.4M | $25.6M | +46.64% |
| Q4 2015 | 2015-12-31 | $87.3M | $85.9M | +6232.29% |
| Q3 2015 | 2015-09-30 | $42.8M | $42.8M | +234993.59% |
| Q2 2015 | 2015-06-30 | $47.5M | $47.5M | +966390.44% |
| Q1 2015 | 2015-03-31 | $54.8M | $54.8M | +806848.33% |
| Q4 2014 | 2014-12-31 | $1.4M | $1.4M | +15096.29% |
| Q3 2014 | 2014-09-30 | $18,217 | $3,262 | +21.81% |
| Q2 2014 | 2014-06-30 | $4,918 | −$13,787 | −73.71% |
| Q1 2014 | 2014-03-31 | $6,793 | $2,767 | +68.73% |
| Q4 2013 | 2013-12-31 | $9,068 | $766 | +9.23% |
| Q3 2013 | 2013-09-30 | $14,955 | $3,494 | +30.49% |
| Q2 2013 | 2013-06-30 | $18,705 | $2,974 | +18.91% |
| Q1 2013 | 2013-03-31 | $4,026 | −$20,342 | −83.48% |
| Q4 2012 | 2012-12-31 | $8,302 | $1,582 | +23.54% |
| Q3 2012 | 2012-09-30 | $11,461 | $931 | +8.84% |
| Q2 2012 | 2012-06-30 | $15,731 | — | — |
| Q1 2012 | 2012-03-31 | $24,368 | — | — |
| Q4 2011 | 2011-12-31 | $6,720 | −$22,678 | −77.14% |
| Q3 2011 | 2011-09-30 | $10,530 | — | — |
| Q4 2010 | 2010-12-31 | $29,398 | — | — |
Kura Oncology total assets trends
Over the last five fiscal years, Kura Oncology's total assets increased from $647.2M to $738.4M, a change of $91.2M. The latest reported quarter, Q2 2026, shows $587.8M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kura Oncology source filings ↗